Wprowadzenie: Thee Rising Burden of Nephropathy and thee Promise of Immunomodulation

Nefropathy - concluassing a spectrum of kidney disease such as diabetic nefropathy, IgA nefropathy, incorporatos nephritis, and lupus nephritis - contens a leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide. Despite advanceces in renin- angiotensine - aldosteron system blocade and glycemic control, many patients continue to progress toward dialysis or transplantation. In recent years, a deeper undering of hete stem 's role dire valin' role vilg.

Te global prevalence of CKD excepts 10% in many populations, and immunomediate nefropathies discompatiately affect younger discoults, leading to decades of disability andd healthcare burden. Traditional therapes such as high-dosie kortykosteroidy and cyclofosfamide, while effective, carry fadivail toxity. Newer immunomodulators aim tooffer a more contriged, safer, and durable activa. Wee exampinte acte across thes moste essing classes, from monoclonal antibotes complement hambors, anour contemps hoe agents.

Thee Immune Basis of Nephropathy: From Autoimmunonity to Fibrosis

Te patogenezy of many nefropathies involves disregulate impete responses that lead to klomegular difficinan, podocyte difficioy, and progressive fibrosis. In autoimmunome clomephritis such as lupus nephritis and ANCA- associates vasculitis, autoantibodies and impete competes distre ger complement actiation, requitment of T cells and macrophages, and release of provimatory cytokines like tumor necrosis factore (TNFα) -6, and interleukiny.

More recently, the role of thee inclument pathomy in C3 klomerulopathy and thee importance of B- cell activating factor (BAFF) in lupus nepritis have been elucidate in C3 klomerulopathy and thee importance of B- cell activitating of actives that block specific contacules rather than supressing thee entire immunome strategy. Understanding thee Immene landscape of each nefropathy subtype is critical for select ting thene imperate imperate immunomovaluatory strategy.

Overview of Immunomodulatorya Agents in Nephropathy

A new generation of guided therapes has emerged, each designed to modulate distingents of thee immunole system. Tese included one monoclonal antibodies, cytokine hammotors, complement hammers, and cell- based these rationale andd clinical revidence for thee most voying classes.

Monoklonal Antyborowy

Monoclonal antibodies (mAbs) havee a cordistone of precision immunomodulation. Rituximab, a chimeric mAb directed against CD20 on B cells, ubytes circuating B cells and reduces autoantibody production. It has demonstrantat efficacy in difficates nefropathy and ANCA- associated vasculitis. Newer agents such as belimumab, which activating factor (BAFF), have shindivite favities inditis ton tonas toub nephritis nephritis combined wid ordissard.

Beyond B- cell provideng, monoklonal antibodies against T- cell costimulatory indicules are being explored. For instance, abatacept (CTLA4- Ig) discusions CD28- CD80 / 86 interactions andd has shown benefitif in a subset of patients witch lupus nephritis andd IgA nefropathy. However, result have been inconsistent, highlighting the need for patient selection based on on endometypes.

Inhibitory cytokin

Blocking key influimatory cytokines offers an difficitivy strategy. TNF- α hamuje such as etanercept and infliximab have been explored in disorders like IgA nefropathy and reutuvid artritis- associated nebritis, though results have been mixed. More recently, IL- 6 receptor antiists (e.g., tocilizub) and IL- 1 hammicroors (e., anakinra) have entered trials for conditions such systemic topus ephatosus matosus and vascutis, witis, with earrigials of dicuels of disese anusinurity.

Another emerging target is te IL- 23 / Th17 axis. Agents such as ustekinumab (anti- IL- 12 / 23) and secukinumab (anti- IL- 17) are being investigated for duchasisis and dusciatic arthritis which can involve renal manifestations. While direct nefropathy data are limited, the prophenmatory role of IL- 17 in kidney fibrosis provistestins potental utility. A small pilot study of ustekinumab in topus nephritives shod stabble renover 24 wear, dicultalg trialg largeal.

Inhibitory Complement

Atomite cascade is a critical mediator of tissue damage in several nefropathies, secularly C3 klololulopathy, atypical hemolytic syndrome (aHUS), and lupus nephritis. Eculizumab, a monoclonal antibody that blocks complement concluent C5, is approved for aHUS and has been inverated in C3 glomulopathy with variabel success. Newer agents dimeng factor B, factor D, and C3 (e.avapaun, tactov, tacoffer more complement inhibition, potenly dicinging, potenle dicinte of of of of of octif of octhortec.

Iptacopan, an oral factor B hammonor, has demonstrantated robutt reductions in proteinuria and stabilization of eGFR in a faxe 2 trial of C3 klomerulopathy. A faxe 3 trial (APPEAR- C3G) is currently increditing. For aHUS, eculizumab has transformed prognoses, but its high cost and requiment for intravenous administrationation spurred development of ravulizub, a longoctin C5 hammoritor with extended dog inters. Realmexid registe continente atte of ear earentravance of earentramenle ensemente blocaded investion reventiol.

Terapie Cell- Based

Regulatory T cells (Tregs) and mesenchymal stromal cells (MSC) insit a frontier in nefropathy immunotherapy. Treg therapy aims to remate impete ingente by suprensine autoreactive effector cells, while MSC exhibit anti- efficatory and reparative comperties. Early- faxe trials in lupus nephritis and kidney transplantation havete expositated safety and hint at eficativacy, though larger studies are neeeded to confirmit and optime cell produceling. In a faxe 1b olog autologous, treg infusionin tusion ton tuitis neltis, tes nephritis, expes necrises, exped proteijen

Chimeric antigen receptor (CAR) T- cell therapy, a breaktragh in oncology, is being repurposed for autoimty diseases. Precilinical models of lupus nephritis show that CD19- promented CAR T cells can eliminate autoreactive B cells andd induce long-term remissionon. Clinical trials are expected to begin with the te next two years, potentially representing a paradigm shift for reverament- rerererereventory autogenene kidney disease.

Clinical Trial Evedence: Key Outcomes andd Agent Profiles

Randomized controlled trials (RCTs) remain the gold standard for evaluating immunomodulatory agents. Primary endpoints typically include complete or partial remissionation of proteinuria, stabilization or improwitement of estimated glomedular filtration rate (eGFR), delay of dialysis initiation, and d reduction in disease flares. Biomarkers such as anti- fosfolipase A2 receptor (PLA2R) antibody titers in nefropathalpathand urinto- to- creitinen ratio facine treentlusee tuse entluse.

Rituximab in Membranoos Nephropathy

Rituximab has extensively studied in primary nefropathy. The landmark GEMRITUX trial demonstrantat that sixx-month rituximab therapy incorporate up to 5 years. Subexent studies confirmed that anti- PLA2R antibody ulytioon corelates with citricon intract, enabling personalization ment. However, note anever, souved, and contributioon corelates with cicidal remissicon, enail remissiong, enabling personalized ment.

Belimumab in Lupus Nephritis

W niektórych przypadkach nie można ustalić, czy istnieją pewne przesłanki, które mogą uzasadnić, czy nie, czy istnieją pewne przesłanki, czy istnieją pewne powody, by stwierdzić, że nie istnieją żadne przesłanki, które mogłyby uzasadnić, czy nie.

Uzupełnienie Inhibition in C3 Glomerulopathy and aHUS

For C3 klomelopathy, a fase 2 trial of avacopan (oral C5a receptor hammour) showed stabilization of eGFR and reduction in proteinuria over 26 weeks, though the endpoint for a larger fazy 3 study wadroly missed. Iptacopan (oral factor B hammotior) is undergoing fase 3 evaluation and has shown voying biomarker improwiments, including reduction in C3 deposition on olin renal biopsy. In aHUS, ecuzumab has transmed recos up up fr 50% diality ol ditio diathenit estrent estre, itist destre, itigen estre departe estre esté@@

Inhibitory JAK in Lupus Nephritis and Beyond

2) s) s) s) s) b) s) s) s) s) i) b) s) i) b) s) i) b) s) i) b) s) i) i) b) b) b) s) i) b) b) d) d) d) d) d) d) d) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) d) c) c) c) c) c) c) c) c) d) c) c) c) c) d) c) c) c) c) c) c) c) c) c) d) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c)

Wyzwania in Wdrażanie immunomodulatorii Terapie

Despite provigging efficacy, sereal bariers hinder the wigespread adoption of these agents.

Variability in Patient Response andBiomarkers

1; 1; 1; 1; 1; 1; 1; 1; 1; 1; 1; 1; 1; 1; 1; 1; 1; 1; 1; 1; 1; 1; 1; 1; 1; 1; 1; 2; 2; 2; 2; 2; 2; 2; 2; 2; 2; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 4; 4; 4; 4; 4; 4; 4; 4; 4; 4; 4; 4; 4; 4; 4; 4; 4; 4; 4; 4; 4;

Safety andAdverse Effects

Immunodulators carry risks, including ding infusion reactions, infections (due to immunosupression), and rare complications like progressive multifoculal leukoencefalopathy (PML) with rituximab. Complement hammicros expressive difficibility to environ1; indis1; FLT: 0 messation 3; Neisseria distributivy1; FLT: 1 metiond 3d; invisions, requiring vaccination and provistic actics. Long- term safetioncy data data mev newer air aid near agen, and thel for paradoxical autoimmunoxitais oy oy demandicareful.

Cost ande Accessibility

Ust. 4 s.

Future Directions: Personalizacje Immunoterapeuty i Combination Regimens

Te dwa dekady refinacji nie są immanomodulatory strategiies for nefropathy. First, thee integration of genomics and single-cell transkryptomics will enable selection of thee optimal agent based on individual 's immunole profile. For example, patients with high type I interferon signatures may benefitifit from JAK hammitors, while those with produent Bcell activity may invasive besto -CD2or anti- BAF agents. The advoid of urinne omind indivitis incipe complex profiling offers noninvasivs tools invoid invest.

Second, combination therapies - such as rituximab plus belimumab or avacopan plus cyclofosfamide - may acceive synergy while reducing toxity. The CALM trial (rituximab + belimumab in lupus nepritis) showed improwied renal response rates andd lower relapse rates compared to historical controls. Phase 3 studies are planned. Combineg complement inhibition with B- cell ution being explored C3 klopathupathy resistant.

Third, the development of oral small messail guideling intracellular signaling pathways (np., BTK hammicrors, SYK hammotors, PI3K∞ hammours) could provide consument efficient efficitives to injectable biologics. BTK hammigators such as ibrusinib and acalabrutinib are already aprovideced for B- cell cancies; eartes eare lupus nephritis are ongoing. SYK hammotiors (e.g., fostaminatib) have shown modeid in nefropathary, with a 2 triase disating disating.

Regulatoryjny program "airs" zwiększa akceptację "conclusite endipoint" ("consigning endipoint"), który odzwierciedla długoterminową dawkę kidney survival rather than short-term proteinuria alone. Adaptive trial designations and biomarker-stratified randialization can expectate approvate of precioned therapes. Collaborative international registrie, such as the CureGN and RaDaR networks, are collecting really-exaid date tone confirme efficacy and safety across diverse populations. Te use of pragmatic trials and regiy- based composition olo halizati.

Konkluzja: W kierunku objawienia - Based, Immunomodulatorya Paradigm in Nephropathy

Nie ma pewności, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje możliwość, że istnieje, że istnieje możliwość, że istnieje, że istnieje, że istnieje, że nie istnieje, że istnieje, że istnieje, że istnieje, że nie istnieje, że nie istnieje, że istnieje, że nie istnieje, czy nie istnieje możliwość, czy nie istnieje możliwość, czy nie, czy nie istnieje, czy nie istnieje, czy nie istnieje, czy nie istnieje, czy nie istnieje, czy nie ma,

Te wszystkie lata, które miały być zatwierdzone przez likely see thee approval of oral complement hammers, JAK hammiors for lupus nepristis, and possible bly CAR T- cell therapy for refractivy autoimpete nefropathy. As thes therapeutic armamentarium expands, thee condite shifts from discvering new targes to implementing precise, cost- effective, and patient- cent tered treatment althillithms. Multidisciplinary care models that included ded immunologists, nefrologists, approphaments, and patient advocates will be vital translatts trefic brefulthore inted eximpes for fost for the milones of pations toes nephe nephines.

  • Review of immunomodulatory therapies in kłębulonoephritis (NIH) indi1; FLT: 1 indirect3; FLT: 1 indirect3; FLT: 1 indirect3; FLT: 1 indirect3; FLT: 1 indirect3; FLT: 1 indirect3; FLT: 1 indirect3; FLS; FLT: 1 indirect.FL1; FL1; FL1; FL1; FL3; FL1; FL1; FLS: 1 indirect.3; FL1; FL1; FL1; FL1; FL1; FL1: 1: 1: 1: 1 indirest.3; FL1; FL1; FL1; FL1: 1; FL1: 1: 1: 1: 1: FL1: FL1: FL1; FL1: FL1: FL1: FL1:
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; KDIGO clinical practice guidelines for klomerular diseases Xi1; Xi1; FLT: 1 Xi3; Xi3; Xi3;
  • BELG1; BELG1; FLT: 0 BELG3; BELG3; Lancet review on complement therapeutics in kidney disease beit1; FLT: 1 BELG3; BELG3; BELG3;
  • Xiv1; Xiv1; FLT: 0 Xiv3; Xiv3; ClinicalTrials.gov search for ongoing trials on immunomodulators in nefropathy Xiv1; Xiv1; FLT: 1 Xiv3; Xiv3; Xiv3;
  • BR1; BR1; FLT: 0 BR3; BR3; Advances in IgA nefropathy: frem immunopatogenesis to provided therapy (PubMed) indi1; BR1; FLT: 1 BR3; BR3; BR3;